Abstract

Abstract Objectives: To clarify the roles of adiponectin receptor (AdipoR) and leptin receptor (ObR) in endometrial carcinoma, expressions of AdipoR-1 and -2 and ObR in endometrial cancer were examined immunohistochemically and relationships to clinicopathological implications were also analyzed. Methods: Under the written informed consent, paraffin-embedded tissues were obtained from 77 patients with endometrial carcinoma and were stained immunohistochemically using antibodies against AdipoR-1, AdipoR-2 and ObR. Results: AdipoR-1, AdipoR-2 and ObR were localized predominantly in the cell membrane and cytoplasm of tumor cells and normal endometrial cells. In 77 cases of endometrial cancer, positive expression was observed in 46 cases (59.7%) for AdipoR-1, 47 cases (61.0%) for AdipoR-2 and 33 cases (42.9%) for ObR. Expression of AdipoR-1 was observed more in stage I cases, G1 tumours, tumors with shallow myometrial invasion, tumors negative for lymphovascular space involvement, cases negative for adnexal invasion, and cases with no lymph node metastasis. However, expressions of AdipoR-2 and ObR showed no relationship to any clinicopathological factors. Kaplan-Meier analyses revealed that progression-free and overall survivals were longer in cases with positive AdipoR-1 expression compared with negative AdipoR-1 expression. Conclusion: Poor expression of AdipoR-1 thus appears to be associated with tumour grade, myometrial invasion, adnexal invasion, lymph-vascular space involvement and lymph-node metastasis, as well as poor prognosis in endometrial cancer. Citation Format: Hiromitsu Yabushita, Keita Iwasaki, Taiki Ueno, Akihiko Wakatsuki. Clinicopathological roles of adiponectin receptor and leptin receptor in endometrial carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4738. doi:10.1158/1538-7445.AM2014-4738

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call